🏛️ Verified NIH Record • Updated 2026-08-20

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (NCT07392190)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (15 items).

Location: Birmingham Clinical Research — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have type 1 diabetes
  • Have taken any of the following antihyperglycemic medications within 90 days before screening:
  • dipeptidyl peptidase-4 (DPP-4) inhibitors
  • amylin analogs
  • insulin
  • Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (187 Sites)

Showing the first 25 of 187 sites.

  • Birmingham Clinical Research — Birmingham, Alabama
  • RIO Clinical Trials - Phoenix — Phoenix, Arizona
  • Headlands Research - Scottsdale — Scottsdale, Arizona
  • Novak Clinical Research - Tucson - North La Cholla Boulevard — Tucson, Arizona
  • Irvine Clinical Research — Irvine, California
  • Scripps Whittier Diabetes Institute — La Jolla, California
  • EndoTrials Center for Clinical Research — La Mesa, California
  • Peninsula Research Associates — Rolling Hills Estates, California
  • Care Access - Sacramento — Sacramento, California
  • Artemis Institute for Clinical Research — San Diego, California
  • Southern California Clinical Research — Santa Ana, California
  • University Clinical Investigators, Inc. — Tustin, California
  • New England Research Associates, LLC — Bridgeport, Connecticut
  • Yale University School of Medicine — New Haven, Connecticut
  • Chase Medical Research, LLC — Waterbury, Connecticut
  • JEM Research Institute — Atlantis, Florida
  • AMR Clinical — Doral, Florida
  • Northeast Research Institute (NERI) — Fleming Island, Florida
  • Jacksonville Center for Clinical Research — Jacksonville, Florida
  • New Horizon Research Center — Miami, Florida
  • St Johns Center for Clinical Research — Saint Augustine, Florida
  • Metabolic Research Institute, Inc. — West Palm Beach, Florida
  • Teak Research Consults - Dunwoody — Dunwoody, Georgia
  • Center for Advanced Research & Education — Gainesville, Georgia
  • Clinical Research Atlanta — Stockbridge, Georgia

📞 Contact the Study Coordinator

Phone: (317) 615-4559

Email: LillyTrials@Lilly.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Overweight

Explore by condition: All Overweight clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗